Amadix Secures €15 Million Loan from EIB to Expand Early Cancer Detection Solutions Across Europe and the U.S.

Amadix Secures €15 Million Loan from EIB to Expand Early Cancer Detection Solutions Across Europe and the U.S.

(IN BRIEF) Amadix, a Spanish biotech company focused on non-invasive blood tests for early cancer detection, has secured a €15 million loan from the European Investment Bank (EIB). This funding, backed by InvestEU, will support Amadix in advancing its blood tests, including PreveCol for colorectal cancer, PancreaDix for pancreatic cancer, and DiagnoLung for lung cancer. The financing will help the company expand internationally, validate PreveCol in the U.S., and bring innovative solutions to the European and U.S. markets. Amadix’s AI-driven approach combines clinical features with protein and miRNA analysis to detect pre-cancerous lesions, aiming to prevent cancer before it develops. This initiative contributes to the EU’s Beating Cancer Plan and promotes the competitiveness of European life sciences industries.

(PRESS RELEASE) LUXEMBOURG, 10-Feb-2025 — /EuropaWire/ — Amadix, a pioneering Spanish biotech company specializing in non-invasive blood tests for the early detection of cancer, has secured a €15 million loan from the European Investment Bank (EIB). This funding will aid the company’s development and commercialization of its groundbreaking medical solutions, focusing on detecting various types of cancer before symptoms arise, significantly improving survival rates for conditions like colorectal cancer.

The loan forms part of the EIB’s support for innovative European medtech startups and aligns with the bank’s strategic commitment to fostering digitalization and technological innovation. This operation is further backed by InvestEU, an EU initiative designed to unlock over €372 billion in investment by 2027, reinforcing Europe’s healthcare and technological advancements.

The financing will support Amadix in advancing its flagship product, PreveCol, a blood test for early colorectal cancer detection. It will also help the company expand its pipeline with new tests, including PancreaDix for pancreatic cancer and DiagnoLung for lung cancer detection. Additionally, the loan will assist Amadix’s international expansion, including the clinical validation of PreveCol in the United States and the company’s broader market entry in both Europe and the U.S.

Amadix, based in Valladolid, is at the forefront of integrating Artificial Intelligence (AI) with cancer diagnostics. Their innovative technology combines clinical features identified by AI with the analysis of proteins and miRNAs in plasma, enabling the early detection of pre-cancerous lesions. The ability to identify and remove these lesions at an early stage can effectively prevent the development of cancer.

Alessandro Izzo, Director of Equity, Growth Capital and Project Finance at EIB, highlighted the importance of supporting European startups like Amadix: “This loan underscores our commitment to innovative European companies developing breakthrough solutions for early cancer detection. We are proud to support the growth of companies like Amadix as part of Europe’s broader strategy to tackle cancer and strengthen its medtech sector.”

The loan, guaranteed by InvestEU, contributes to the EU’s Beating Cancer Plan and the EIB’s strategic priority of accelerating technological innovation. Rocío Arroyo, CEO and founder of Amadix, expressed her gratitude, stating, “The EIB’s support enables us to expand our disruptive blood tests for early cancer detection to European and U.S. markets, bringing innovative solutions like liquid biopsy to those in need and helping to reduce cancer mortality rates worldwide.”

This investment is not only expected to enhance scientific knowledge but also boost Europe’s competitiveness by strengthening its life sciences industry and supporting the innovative capabilities of European businesses.

Background information

EIB

The European Investment Bank (EIB) is the long-term lending institution of the European Union owned by its Member States. It finances investments that contribute towards EU policy goals. EIB projects bolster competitiveness, drive innovation, promote sustainable development, enhance social and territorial cohesion, and support a just and swift transition to climate neutrality.

InvestEU

The InvestEU programme provides the European Union with crucial long-term funding by leveraging substantial private and public funds in support of a sustainable recovery. It also helps mobilise private investments for the European Union’s policy priorities, such as the European Green Deal and the digital transition. The InvestEU programme brings together under one roof the multitude of EU financial instruments currently available to support investment in the European Union, making funding for investment projects in Europe simpler, more efficient and more flexible. The programme consists of three components: the InvestEU Fund, the InvestEU Advisory Hub and the InvestEU Portal. The InvestEU Fund is implemented through financial partners that will invest in projects using the EU budget guarantee of €26.2 billion. The entire budget guarantee will back the investment projects of the implementing partners, increase their risk-bearing capacity and thus mobilise at least €372 billion in additional investment.”

Amadix

Amadix is a leading molecular diagnostics company focused on liquid biopsy, developing innovative blood tests for early cancer detection. The company´s mission is to extend people´s lives by developing disruptive technologies that can detect tumours years in advance before the symptoms appear.  Amadix´s approach combines molecular data from blood samples with patient’s clinical information, extracted from diagnostic images and electronic medical records. Their technology, based on machine learning algorithms, is designed for use in screening and health prevention programmes, positioning itself as a complementary tool to promote precision medicine and cancer prevention.

Media Contact:

Maite Cordero
m.corderomunoz@eib.org
+34 606 66 82 62

Press Office
press@eib.org
+352 43791

SOURCE: European Investment Bank